Biodexa Pharmaceuticals (BDRX) Return on Invested Capital (2020 - 2024)

Biodexa Pharmaceuticals has reported Return on Invested Capital for 4 years, with the latest figure at 0.03% in Q4 2024.

• Quarterly Return on Invested Capital changed N/A year-over-year to 0.03% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.03% (changed N/A YoY) and the FY2025 annual result came in at 0.02%, changed 0.0% from the prior year.
• Return on Invested Capital grew to 0.03% in Q4 2024 per BDRX's latest filing, from 0.09% in the prior quarter.
• Over five years, Return on Invested Capital peaked at 0.03% in Q4 2024 and troughed at 0.31% in Q3 2021.
• A 4-year average of 0.15% and a median of 0.09% in 2020 frame the typical range for Return on Invested Capital.
• The sharpest annual moves came in 2021 and 2022: Return on Invested Capital fell 23 bps in 2021, then advanced 11 bps in 2022.
• Over 4 years, Return on Invested Capital stood at 0.09% in 2020, then plunged by 118 bps to 0.2% in 2021, then soared by 56 bps to 0.09% in 2022, then jumped by 65 bps to 0.03% in 2024.
• According to Business Quant data, Return on Invested Capital over the past three periods registered 0.03%, 0.09%, and 0.26% for Q4 2024, Q4 2022, and Q3 2022 respectively.